KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Gains from Sales and Divestitures (2016 - 2018)

Teva Pharmaceutical Industries' Gains from Sales and Divestitures history spans 9 years, with the latest figure at $1.6 million for Q4 2018.

  • For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2018, changed N/A, and an annual FY2018 reading of $1.6 million, changed N/A over the prior year.
  • Gains from Sales and Divestitures for Q4 2018 was $1.6 million at Teva Pharmaceutical Industries, up from $830000.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $1.6 million in Q4 2018, with the low at -$1.1 million in Q4 2015.
  • Average Gains from Sales and Divestitures over 4 years is $625500.0, with a median of $988000.0 recorded in 2014.
  • Year-over-year, Gains from Sales and Divestitures tumbled 197.03% in 2015 and then skyrocketed 174.64% in 2016.
  • Tracing TEVA's Gains from Sales and Divestitures over 4 years: stood at $1.1 million in 2014, then tumbled by 197.03% to -$1.1 million in 2015, then skyrocketed by 174.64% to $830000.0 in 2016, then soared by 97.35% to $1.6 million in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Gains from Sales and Divestitures are $1.6 million (Q4 2018), $830000.0 (Q4 2016), and -$1.1 million (Q4 2015).